Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

被引:11
|
作者
Quan, Hongzhi [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Sixuan [1 ,2 ,3 ,4 ,5 ,6 ]
Shan, Zhongyan [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Ziyi [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Tianjun [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Yanjia [1 ,2 ,3 ,4 ,5 ,6 ]
Yao, Zhigang [1 ,2 ,3 ,4 ,6 ,7 ]
Fang, Liangjuan [8 ,9 ]
机构
[1] Cent South Univ, Hunan Key Lab Oral Hlth Res, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Hunan 3D Printing Engn Res Ctr Oral Care, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Hunan Clin Res Ctr Oral Major Dis & Oral Hlth, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Dept Oral Maxillofacial Surg, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha 410008, Hunan, Peoples R China
[8] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[9] Cent South Univ, Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
基金
中国博士后科学基金;
关键词
Oral squamous cell carcinoma; Oral submucous fibrosis; Programmed death ligand-1; Programmed death 1; Prognosis; PD-L1; EXPRESSION; CANCER; MICROENVIRONMENT; BLOCKADE; GRADE;
D O I
10.1016/j.archoralbio.2020.104916
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. Methods: PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. Results: The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). Conclusions: The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [22] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [23] Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
  • [25] Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma
    Todoroki, Keita
    Abe, Yushi
    Matsuo, Katsuhisa
    Nomura, Hidetoshi
    Kawahara, Akihiko
    Nakamura, Yoshiaki
    Nakamura, Moriyoshi
    Seki, Naoko
    Kusukawa, Jingo
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [26] Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
    Khan, Moomal Aslam
    Syed, Serajuddaula
    Wahab, Noor Ui
    Butt, Saima Akram
    ANNALS ABBASI SHAHEED HOSPITAL & KARACHI MEDICAL & DENTAL COLLEGE, 2019, 24 (04): : 187 - 194
  • [27] Dynamic contrast-enhanced MRI as a predictor of programmed death ligand-1 expression in patients with oral squamous cell carcinoma
    Tekiki, Nouha
    Fujita, Mariko
    Okui, Tatsuo
    Kawai, Hotaka
    Oo, May
    Kawazu, Toshiyuki
    Hisatomi, Miki
    Okada, Shunsuke
    Takeshita, Yohei
    Barham, Majd
    Nagatsuka, Hitoshi
    Yanagi, Yoshinobu
    Asaumi, Jun-Ichi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [28] Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma
    Monsrud, Ashley L.
    Avadhani, Vaidehi
    Mosunjac, Marina B.
    Flowers, Lisa
    Krishnamurti, Uma
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2022, 146 (09) : 1094 - 1101
  • [29] Programmed death ligand-1 (PD-L1) expression in penile squamous cell carcinoma
    Wang, Jennifer
    Rodriguez, Jaime
    Rao, Priya
    Pettaway, Curtis Alvin
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns
    Nishino, Mizuki
    Hatabu, Hiroto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14)